Background And Purpose: Incidence of breast cancer is increasing and seems to be associated with fatty foods, metabolism, and so on. The fat mass and obesity associated gene (FTO) has been intensively investigated in diabetes, obesity and the other diseases. Previous studies have reported that FTO SNPs are associated with breast cancer risk. Here, we investigated the expression of FTO in human breast cancer tissues and its relationship with the clinicopathological features.

Methods: In this retrospective study, tissues from 79 patients with breast cancer were collected, as well as 43 cases of adjacent breast tissues. Immunohistochemistry was used to detect the expression of FTO. Statistical analysis was performed to assess the association between FTO expression and the clinicopathological features of breast cancer.

Results: FTO was expressed in both mammary epithelial and breast cancer tissues, but with different degree. The expression level of FTO in breast cancer tissues was significantly higher than that in the adjacent breast tissues (P < 0.001). The percentage of FTO-positive expression in cases with hormone receptor (HR) negative and HER2 amplification was significantly higher than that in those with HR positive and HER2 negative (P = 0.001, P < 0.001). The positivity rate of FTO in breast cancer with P53 positive and histological grade 3 seemed to be higher than that with P53 negative and histological grade 1 or 2, respectively (P = 0.077, P = 0.082). There was no association between FTO expression and age, T stage, LN status, TNM stage, Ki67, and BMI in breast cancer. Besides, FTO expression in HER2-overexpressed subtype was significantly higher than that in Triple-negative and Luminal A/B1 subtypes (P < 0.001).

Conclusion: Our study suggests that FTO expression may have a vital role in the carcinogenesis of breast cancer, especially in HER2-overexpressed breast cancer.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4680493PMC

Publication Analysis

Top Keywords

breast cancer
44
fto expression
16
breast
14
fto
12
fto breast
12
cancer tissues
12
cancer
11
fat mass
8
mass obesity
8
obesity associated
8

Similar Publications

Phyllodes tumours of the breast are rare fibroepithelial neoplasms classified histologically into benign, borderline, or malignant; each requiring different treatment strategies. The infrequency of presentation can result in diagnostic and management variability. The aim is to provide evidence-based or expert consensus recommendations for multidisciplinary teams managing patients with phyllodes tumours.

View Article and Find Full Text PDF

The breast cancer resistance protein (BCRP/ABCG2) plays a major role in the multidrug resistance of cancers toward chemotherapeutic treatments. It was demonstrated that cholesterol regulates the ABCG2 activity, suggesting that lower levels of membrane cholesterol decrease the ABCG2 activity in mammalian cells. However, the precise mechanism remains unclear.

View Article and Find Full Text PDF

This study evaluated the association between age at first full-term pregnancy (FFTP) and mammographic breast density (MBD) in postmenopausal women. 1,034 women, age 50-69y, were recruited from the Flemish (Belgium) population-based breast cancer screening program. Participants completed a questionnaire on lifestyle and reproductive factors.

View Article and Find Full Text PDF

Adenoid cystic carcinoma (ACC) of the breast is an exceptionally rare malignancy, accounting for less than 0.1% of all breast cancers. Despite its favorable prognosis, optimal management remains undefined due to its rarity and lack of consensus guidelines.

View Article and Find Full Text PDF

Integrated Network Pharmacology, Machine Learning and Experimental Validation to Identify the Key Targets and Compounds of for the Treatment of Breast Cancer.

Onco Targets Ther

January 2025

Affiliated Yongkang First People's Hospital and School of Pharmaceutical Sciences, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.

Background: TiaoShenGongJian (TSGJ) decoction, a traditional Chinese medicine for breast cancer, has unknown active compounds, targets, and mechanisms. This study identifies TSGJ's key targets and compounds for breast cancer treatment through network pharmacology, machine learning, and experimental validation.

Methods: Bioactive components and targets of TSGJ were identified from the TCMSP database, and breast cancer-related targets from GeneCards, PharmGkb, and RNA-seq datasets.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!